Autoimmune hepatitis in Iran: What we know, what we don't know and requirements for better management

Hepatitis Monthly

Volumn 12, Issue 2, 2012, Pages 73-76

  Shafiei, Mostafa ^a   Alavian, Sayed Moayed ^a  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Autoimmune Iran treatment; Hepatitis

Indexed keywords

ASPARTATE AMINOTRANSFERASE; AUTOANTIBODY; AZATHIOPRINE; BUDESONIDE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; RITUXIMAB; TACROLIMUS; URSODEOXYCHOLIC ACID;

ADJUVANT THERAPY; ARTICLE; AUTOIMMUNE HEPATITIS; DRUG MEGADOSE; HUMAN; IRAN; LIVER BIOPSY; LOW DRUG DOSE; MONOTHERAPY; RECOMMENDED DRUG DOSE; REMISSION;

EID: 84858258560     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/hepatmon.840     Document Type: Article

References (38)

1. Waldenstrom JG. Leber, Blutproteine und Nahrungseiweiss. Dtsch Ges Verdau Stoffwechselkr. 1950;15:113-9.
2. Aghazadeh R, Forootan M, Shahraz S. Epidemiological indices of 31 patients with autoimmune hepatitis and their response to treatment. Pejouhesh. 2003;27(1):53.
3. Roshan Del D, Rezaei Lashkajani M, Hekmat Doost A, Mohaghegh Shalmani H, Ghaziani T, Sendi H, et al. Clinical and laboratory characteristics of Autoimmune Hepatitis. Tabib-e-Shargh. 2005;12(4):253-60.
4. Mirzaagha F, Azali SH, Islami F, Zamani F, Khalilipour E, Khatibian M, et al. Coeliac disease in autoimmune liver disease: a cross-sectional study and a systematic review. Dig Liver Dis. 2010;42(9):620-3.
5. Sima H, Hekmatdoost A, Ghaziani T, Alavian SM, Mashayekh A, Zali MR. The prevalence of celiac autoantibodies in hepatitis patients. Iran J Allergy Asthma Immunol. 2010;9(3):157-62.
6. Iranikhah A, Najafi-Sani M, Khodadad A, Saneian H, Mir-Nasseri M, Aghaali M. Cyclosporine therapy for autoimmune hepatitis in children. Govaresh. 2011;15(4):254-62.
7. Malekzadeh R, Nasseri-Moghaddam S, Kaviani MJ, Taheri H, Kamalian N, Sotoudeh M. Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig Dis Sci. 2001;46(6):1321-7.
8. Malekzadeh R, Mohamadnejad M, Nasseri-Moghaddam S, Rakhshani N, Tavangar SM, Sohrabpour AA, et al. Reversibility of cirrhosis in autoimmune hepatitis. Am J Med. 2004;117(2):125-9.
9. Mohamadnejad M, Malekzadeh R, Nasseri-Moghaddam S, Hagh-Azali S, Rakhshani N, Tavangar SM, et al. Impact of immunosuppressive treatment on liver fibrosis in autoimmune hepatitis. Dig Dis Sci. 2005;50(3):547-51.
10. Alidoost L, Zafarghandi M, Agah M, Sandi H, Zali M. Glutathion- S-transferase M1, T1 and P1 Gene Polymorphisms in Autoimmune Hepatitis. Pejouhesh. 2006;30(2):161-7.
11. Esteghamat F, Noorinayer B, Sanati MH, Hekmatdoost A, Zafarghandi M, Shalmani HM, et al. C77G mutation in protein tyrosine phosphatase CD45 gene and autoimmune hepatitis. Hepatol Res. 2005;32(3):154-7.
12. Hajialiasgar S, Agah M, Rezvani M, Zali M. CTLA-4 polymorphism at position 49 in exon 1 and susceptibility to type 1 autoimmune hepatitis. Med Sci J Islamic Azad Univ, Tehran Med Branch. 2006;15(4):173-7.
13. Hekmatdoost A, Ghaziani T, Esteghamathanzaie F, Alavian S, Mohaghegh H, Zali M. Transfusion transmitted virus and autoimmune hepatitis. Is there any association? Saudi Med J. 2004;25(11):1760-1.
14. Malekzadeh Z, Haghazali S, Sepanlou S, Vahedi H, Merat S, Sotoudeh M, et al. Clinical Features and Long Term Outcome of 102 Treated Autoimmune Hepatitis Patients. Hepat Mon. 2012;12(2):92-9.
15. Ngu JH, Bechly K, Chapman BA, Burt MJ, Barclay ML, Gearry RB, et al. Population-based epidemiology study of autoimmune hepatitis: a disease of older women? J Gastroenterol Hepatol. 2010;25(10):1681-6.
16. Hurlburt KJ, McMahon BJ, Deubner H, Hsu-Trawinski B, Williams JL, Kowdley KV. Prevalence of autoimmune liver disease in Alaska Natives. Am J Gastroenterol. 2002;97(9):2402-7.
17. Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol. 1998;33(1):99-103.
18. Milkiewicz P, Hubscher SG, Skiba G, Hathaway M, Elias E. Recurrence of autoimmune hepatitis after liver transplantation. Transplantation. 1999;68(2):253-6.
19. Wiesner RH, Demetris AJ, Belle SH, Seaberg EC, Lake JR, Zetterman RK, et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology. 1998;28(3):638-45.
20. Saberifiroozi M, Serati AR, Malekhosseini SA, Salahi H, Bahador A, Lankarani KB, et al. Analysis of patients listed for liver transplantation in Shiraz, Iran. Indian J Gastroenterol. 2006;25(1):11-3.
21. Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology. 1993;18(4):998-1005.
22. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31(5):929-38.
23. Rafeey M, Kianrad M, Hasani A. Autoimmune hepatitis in Iranian children. Indian J Gastroenterol. 2007;26(1):11-3.
24. Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51(6):2193-213.
25. Gleeson D, Heneghan MA. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut. 2011;60(12):1611-29.
26. Adams LA, Lindor KD, Angulo P. The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic Fatty liver disease. Am J Gastroenterol. 2004;99(7):1316-20.
27. Mackay IR. Chronic hepatitis: effect of prolonged suppressive treatment and comparison of azathioprine with prednisolone. Q J Med. 1968;37(147):379-92.
28. Czaja AJ. Autoimmune hepatitis in special patient populations. Best Pract Res Clin Gastroenterol. 2011;25(6):689-700.
29. Soloway RD, Summerskill WH, Baggenstoss AH, Geall MG, Gitnick GL, Elveback IR, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology. 1972;63(5):820-33.
30. Czaja AJ, Wolf AM, Baggenstoss AH. Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy: correlation of serum transaminase and gamma globulin levels with histologic features. Gastroenterology. 1981;80(4):687-92.
31. Montano-Loza AJ, Carpenter HA, Czaja AJ. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol. 2007;102(5):1005-12.
32. Muratori L, Muratori P, Lanzoni G, Ferri S, Lenzi M. Application of the 2010 American Association for the study of liver diseases criteria of remission to a cohort of Italian patients with autoimmune hepatitis. Hepatology. 2010;52(5):1857; author reply -8.
33. Verma S, Gunuwan B, Mendler M, Govindrajan S, Redeker A. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol. 2004;99(8):1510-6.
34. Jackson LD, Song E. Cyclosporin in the treatment of corticosteroid resistant autoimmune chronic active hepatitis. Gut. 1995;36(3):459-61.
35. Sherman KE, Narkewicz M, Pinto PC. Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis. J Hepatol. 1994;21(6):1040-7.
36. Manns MP, Woynarowski M, Kreisel W, Lurie Y, Rust C, Zuckerman E, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology. 2010;139(4):1198-206.
37. Zachou K, Gatselis N, Papadamou G, Rigopoulou EI, Dalekos GN. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatmentnaive patients. J Hepatol. 2011;55(3):636-46.
38. Jothimani D, Cramp ME, Mitchell JD, Cross TJ. Treatment of autoimmune hepatitis: a review of current and evolving therapies. J Gastroenterol Hepatol. 2011;26(4):619-27.